The drug targets an immune molecule called interleukin-23 which has been shown to contribute to cancer-causing inflammation.
Sarcomas, which affect other connective tissues such as muscle and tendons, can often be dismissed for other symptoms."Lumps can be attributed to growing pains. We often see delays in diagnosis in that population," he said.The cure rate stands at about 67 per cent, but there hasn't been any advances beyond surgery and chemotherapy.
Repurposing the drug for cancer follows the results of a study by Garvan researchers which showed the immune molecule is central to sarcomas developing in animal models.
Source: Healthcare Press (healthcarepress.net)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: